Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
November 19, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2026-181

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "Company"), received a notice from the National Medical Products Administration (NMPA) approving an additional indication for the Company's self-developed Class 1 innovative drug, Fosrolapitant and Palonosetron Hydrochloride for Injection, which is China's first ultra-long-acting, original dual-target antiemetic injection. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Fosrolapitant and Palonosetron Hydrochloride for Injection

Dosage Form: Injection

Strength: Fosrolapitant 218 mg and palonosetron hydrochloride 0.25 mg (calculated based on $C_{19}H_{24}N2O$)

Registration Category: Chemical Drug Class 2.4

Acceptance No.: CXHS2600019

Prescription Drug/Over-the-Counter Drug: Prescription drug

Review Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and other relevant provisions, this product has been reviewed and found to meet the applicable requirements for drug registration.

Registration is approved, and a Drug Registration Certificate is issued. Approved indication: This product is indicated for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (MEC) in adults.

II. Previously Approved Indications of the Drug

Fosrolapitant and Palonosetron Hydrochloride for Injection was approved for marketing in China in May 2025 for the prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy (HEC) in adults.

III. Other Information of the Drug

Among patients receiving MEC, approximately 50% experience chemotherapy-induced nausea and vomiting (CINV), particularly during the delayed phase [1]. In clinical practice, nausea and vomiting associated with MEC are primarily managed through prophylaxis. Common regimens include a 5-hydroxytryptamine 3 receptor antagonist (5-HT3 RA), with or without a neurokinin-1 receptor antagonist (NK-1 RA), plus dexamethasone, in dual- or triple-drug combinations. Prophylactic medication is essential for controlling nausea and vomiting. However, adherence to clinical guidelines remains suboptimal because of factors such as the complexity of combination regimens, failure to adequately anticipate delayed-phase emesis, and missed doses at home.

Fosrolapitant and Palonosetron Hydrochloride for Injection is a combination formulation that inhibits the emetic reflex by antagonizing the NK-1 and 5-HT3 receptor pathways simultaneously. Its differentiated features include high solubility, a favorable safety profile, and a long duration of action. With an ultra-long half-life of nearly 8 days, this product requires only one dose per chemotherapy cycle to cover the acute, delayed, and extended-delayed phases of CINV. Based on available information, overseas-marketed combination products that antagonize NK-1 and 5-HT3 receptors include Helsinn Healthcare’s AKYNZEO intravenous formulation (fosnetupitant/palonosetron) and oral capsule formulation (netupitant/palonosetron). Both products are marketed in China. As of the date of this announcement, cumulative R&D investment in projects related to Fosrolapitant and Palonosetron Hydrochloride for Injection is approximately RMB 259.50 million (unaudited).

IV. Risk Warning

The Company places great importance on drug R&D and strictly controls quality and safety throughout drug R&D, manufacturing, and sales processes. However, upon obtaining approval letter, the drug's production and sales may be subject to uncertainties. Investors are kindly advised to be prudent in investment decisions, paying attention to the risks involved.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

November 19, 2026

[1] Zhang L, Li YH, Wang DS, et al. Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2026;44(16_suppl):11006.